Screener
Fulgent Genetics, Inc. FLGT Therapeutic Development — Cost Of Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Three Months Ended March 31, 2026 | Laboratory Services | Therapeutic Development | Total |
|---|---|---|---|
| Revenue | $71,051 | $87 | $71,138 |
| Less: | |||
| Adjusted cost of revenue | 48,179 | 8 | 48,187 |
| Adjusted research and development | 6,461 | 4,178 | 10,639 |
| Adjusted selling and marketing | 11,576 | — | 11,576 |
| Adjusted general and administrative | 20,052 | 357 | 20,409 |
| Total adjusted operating loss | $(15,217) | $(4,456) | $(19,673) |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s therapeutic development — cost of revenue?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — cost of revenue of $8K in Q1 2026.
- What does therapeutic development — cost of revenue mean?
- This reflects the direct costs incurred to generate revenue within the therapeutic development segment, including materials, labor, and overhead directly attributable to these activities. Monitoring this metric helps assess the direct profitability and cost efficiency of the segment's commercial operations.
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — cost of revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude